CA3116576A1 - Lipids for lipid nanoparticle delivery of active agents - Google Patents
Lipids for lipid nanoparticle delivery of active agents Download PDFInfo
- Publication number
- CA3116576A1 CA3116576A1 CA3116576A CA3116576A CA3116576A1 CA 3116576 A1 CA3116576 A1 CA 3116576A1 CA 3116576 A CA3116576 A CA 3116576A CA 3116576 A CA3116576 A CA 3116576A CA 3116576 A1 CA3116576 A1 CA 3116576A1
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- compound
- optionally substituted
- saturated
- unsaturated
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C211/09—Diamines
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862747521P | 2018-10-18 | 2018-10-18 | |
| US201862747557P | 2018-10-18 | 2018-10-18 | |
| US62/747,521 | 2018-10-18 | ||
| US62/747,557 | 2018-10-18 | ||
| PCT/US2019/056944 WO2020081938A1 (en) | 2018-10-18 | 2019-10-18 | Lipids for lipid nanoparticle delivery of active agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3116576A1 true CA3116576A1 (en) | 2020-04-23 |
Family
ID=68468848
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3116576A Pending CA3116576A1 (en) | 2018-10-18 | 2019-10-18 | Lipids for lipid nanoparticle delivery of active agents |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12583816B2 (https=) |
| EP (1) | EP3867225A1 (https=) |
| JP (2) | JP7543259B2 (https=) |
| AU (2) | AU2019361129A1 (https=) |
| CA (1) | CA3116576A1 (https=) |
| IL (1) | IL282288A (https=) |
| WO (1) | WO2020081938A1 (https=) |
Families Citing this family (128)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP3596112A2 (en) | 2017-03-17 | 2020-01-22 | Newcastle University | Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy |
| WO2018191657A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP4501322A3 (en) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| MY208145A (en) | 2018-06-18 | 2025-04-18 | Res Inst Nationwide Childrens Hospital | Adeno-associated virus vector delivery of muscle specific micro-dystrophin to treat muscular dystrophy |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
| CN114729376A (zh) | 2019-09-23 | 2022-07-08 | 欧米茄治疗公司 | 用于调节肝细胞核因子4α(HNF4α)基因表达的组合物和方法 |
| EP4048807A1 (en) | 2019-09-23 | 2022-08-31 | Omega Therapeutics, Inc. | Compositions and methods for modulating apolipoprotein b (apob) gene expression |
| CA3173528A1 (en) | 2020-03-11 | 2021-09-16 | Omega Therapeutics, Inc. | Compositions and methods for modulating forkhead box p3 (foxp3) gene expression |
| MX2022012683A (es) | 2020-04-09 | 2023-01-11 | Verve Therapeutics Inc | Edicion de bases de pcsk9 y metodos de uso de la misma para el tratamiento de enfermedades. |
| EP4153223A1 (en) | 2020-05-20 | 2023-03-29 | Flagship Pioneering Innovations VI, LLC | Immunogenic compositions and uses thereof |
| IL298362A (en) | 2020-05-20 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Coronavirus antigen compositions and their uses |
| WO2021243301A2 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| KR20230029685A (ko) | 2020-05-29 | 2023-03-03 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | Trem 조성물 및 이에 관련된 방법 |
| IL299094A (en) | 2020-06-15 | 2023-02-01 | Res Inst Nationwide Childrens Hospital | Administration of an adeno-associated virus vector for muscular dystrophies |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| AU2021336976A1 (en) | 2020-09-03 | 2023-03-23 | Flagship Pioneering Innovations Vi, Llc | Immunogenic compositions and uses thereof |
| EP4228658A4 (en) | 2020-10-14 | 2025-02-19 | George Mason Research Foundation, Inc. | IONIZABLE LIPIDS AND METHODS FOR THE PRODUCTION AND USE THEREOF |
| IL303886A (en) | 2020-12-23 | 2023-08-01 | Flagship Pioneering Inc | Compositions of modified trems and uses thereof |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| EP4313109A1 (en) | 2021-03-31 | 2024-02-07 | Flagship Pioneering Innovations V, Inc. | Thanotransmission polypeptides and their use in treating cancer |
| EP4367242A2 (en) | 2021-07-07 | 2024-05-15 | Omega Therapeutics, Inc. | Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| CA3229889A1 (en) | 2021-09-03 | 2023-03-09 | Glaxosmithkline Biologicals Sa | Substitution of nucleotide bases in self-amplifying messenger ribonucleic acids |
| US20240398940A1 (en) | 2021-09-03 | 2024-12-05 | CureVac SE | Novel lipid nanoparticles for delivery of nucleic acids |
| AU2022341440A1 (en) * | 2021-09-10 | 2024-05-02 | Maxirna (Shanghai) Pharmaceutical Co., Ltd. | Ionizable lipids, their preparation and application in gene delivery |
| MX2024003262A (es) | 2021-09-17 | 2024-06-19 | Flagship Pioneering Innovations Vi Llc | Composiciones y metodos para producir poliribonucleotidos circulares. |
| CA3235625A1 (en) | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vi, Llc | Compositions and methods for purifying polyribonucleotides |
| US20250295755A1 (en) | 2021-10-22 | 2025-09-25 | Sail Biomedicines, Inc. | Mrna vaccine composition |
| EP4422698A1 (en) | 2021-10-29 | 2024-09-04 | CureVac SE | Improved circular rna for expressing therapeutic proteins |
| CA3238764A1 (en) | 2021-11-23 | 2023-06-01 | Siddharth Patel | A bacteria-derived lipid composition and use thereof |
| IL312965A (en) | 2021-11-24 | 2024-07-01 | Flagship Pioneering Innovations Vi Llc | Immunogenic compositions and their uses |
| CN118401544A (zh) | 2021-11-24 | 2024-07-26 | 旗舰创业创新六公司 | 水痘-带状疱疹病毒免疫原组合物及其用途 |
| EP4436984A1 (en) | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| KR20240118174A (ko) | 2021-12-17 | 2024-08-02 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 변성 조건 하에서의 원형 rna의 풍부화를 위한 방법 |
| EP4452239A1 (en) | 2021-12-20 | 2024-10-30 | Sail Biomedicines, Inc. | Compositions comprising mrna and lipid reconstructed plant messenger packs |
| EP4453201A1 (en) | 2021-12-22 | 2024-10-30 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| KR20240118881A (ko) | 2021-12-23 | 2024-08-05 | 플래그쉽 파이어니어링 이노베이션스 브이아이, 엘엘씨 | 항푸소제닉 폴리펩티드를 인코딩하는 원형 폴리리보뉴클레오티드 |
| US20250099614A1 (en) | 2022-01-28 | 2025-03-27 | CureVac SE | Nucleic acid encoded transcription factor inhibitors |
| WO2023177904A1 (en) | 2022-03-18 | 2023-09-21 | Modernatx, Inc. | Sterile filtration of lipid nanoparticles and filtration analysis thereof for biological applications |
| KR20240166554A (ko) | 2022-03-25 | 2024-11-26 | 세일 바이오메디슨스, 인크. | 신규한 이온화 가능 지질 및 지질 나노입자, 및 이를 사용하는 방법 |
| WO2023196634A2 (en) | 2022-04-08 | 2023-10-12 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| CA3257006A1 (en) | 2022-05-09 | 2023-11-16 | Flagship Pioneering Innovations Vi, Llc | TREM COMPOSITIONS AND METHODS OF USE FOR TREATING PROLIFERATIVE DISORDERS |
| TW202409283A (zh) | 2022-05-13 | 2024-03-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 雙股ｄｎａ組合物及相關方法 |
| WO2023218420A1 (en) | 2022-05-13 | 2023-11-16 | Janssen Pharmaceuticals, Inc. | Mrna compositions for inducing latent hiv-1 reversal |
| US20250345407A1 (en) | 2022-05-25 | 2025-11-13 | CureVac SE | Nucleic acid based vaccine encoding an escherichia coli fimh antigenic polypeptide |
| WO2023242817A2 (en) | 2022-06-18 | 2023-12-21 | Glaxosmithkline Biologicals Sa | Recombinant rna molecules comprising untranslated regions or segments encoding spike protein from the omicron strain of severe acute respiratory coronavirus-2 |
| US20250179492A1 (en) | 2022-06-22 | 2025-06-05 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| EP4565604A2 (en) | 2022-08-01 | 2025-06-11 | Flagship Pioneering Innovations VII, LLC | Immunomodulatory proteins and related methods |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| WO2024044147A1 (en) | 2022-08-23 | 2024-02-29 | Modernatx, Inc. | Methods for purification of ionizable lipids |
| US20260060926A1 (en) | 2022-08-31 | 2026-03-05 | Sail Biomedicines, Inc. | Novel ionizable lipids and lipid nanoparticles and methods of using the same |
| US20240174732A1 (en) | 2022-10-05 | 2024-05-30 | Flagship Pioneering Innovations V, Inc. | Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| EP4612296A1 (en) | 2022-10-31 | 2025-09-10 | Flagship Pioneering Innovations VI, LLC | Compositions and methods for purifying polyribonucleotides |
| TW202434728A (zh) | 2022-11-08 | 2024-09-01 | 美商旗艦先鋒創新有限責任公司 | 用於產生環狀多核糖核苷酸的組成物和方法 |
| WO2024102434A1 (en) | 2022-11-10 | 2024-05-16 | Senda Biosciences, Inc. | Rna compositions comprising lipid nanoparticles or lipid reconstructed natural messenger packs |
| TW202430215A (zh) | 2022-12-14 | 2024-08-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 用於將治療劑遞送至骨之組成物和方法 |
| WO2024133160A1 (en) | 2022-12-19 | 2024-06-27 | Glaxosmithkline Biologicals Sa | Hepatitis b compositions |
| WO2024151583A2 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations Vii, Llc | Vaccines and related methods |
| US20240252520A1 (en) | 2023-01-09 | 2024-08-01 | Beth Israel Deaconess Medical Center, Inc. | Therapeutic agents and their use for treating chronic wounds |
| WO2024151687A1 (en) | 2023-01-09 | 2024-07-18 | Flagship Pioneering Innovations V, Inc. | Genetic switches and their use in treating cancer |
| WO2024151673A2 (en) | 2023-01-09 | 2024-07-18 | President And Fellows Of Harvard College | Recombinant nucleic acid molecules and their use in wound healing |
| CN121057577A (zh) | 2023-01-27 | 2025-12-02 | 赛欧生物医药股份有限公司 | 经修饰的脂质组合物及其用途 |
| WO2024167885A1 (en) | 2023-02-06 | 2024-08-15 | Flagship Pioneering Innovations Vii, Llc | Immunomodulatory compositions and related methods |
| CN121263425A (zh) | 2023-02-13 | 2026-01-02 | 旗舰创业创新第七有限责任公司 | 含可裂解接头的可电离脂质和用于治疗性组合物的脂质载体 |
| IL322378A (en) | 2023-02-17 | 2025-09-01 | Flagship Pioneering Innovations Vii Llc | DNA compositions containing modified cytosine |
| EP4665405A1 (en) | 2023-02-17 | 2025-12-24 | Flagship Pioneering Innovations VII, LLC | Dna compositions comprising modified uracil |
| WO2024184500A1 (en) | 2023-03-08 | 2024-09-12 | CureVac SE | Novel lipid nanoparticle formulations for delivery of nucleic acids |
| CN121358494A (zh) | 2023-03-15 | 2026-01-16 | 旗舰创业创新第六有限责任公司 | 免疫原性组合物及其用途 |
| EP4680750A1 (en) | 2023-03-15 | 2026-01-21 | Flagship Pioneering Innovations VI, LLC | Compositions comprising polyribonucleotides and uses thereof |
| EP4695393A1 (en) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Modified trems, compositions, and related methods thereof |
| EP4695391A1 (en) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Trems for use in correction of missense mutations |
| WO2024220625A1 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Delivery of polynucleotides from lipid nanoparticles comprising rna and ionizable lipids |
| WO2024220752A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Rna therapeutic compositions |
| WO2024220712A2 (en) | 2023-04-19 | 2024-10-24 | Sail Biomedicines, Inc. | Vaccine compositions |
| WO2024220746A2 (en) | 2023-04-21 | 2024-10-24 | Flagship Pioneering Innovations Vii, Llc | Rnai agents targeting fatty acid synthase and related methods |
| WO2024230934A1 (en) | 2023-05-11 | 2024-11-14 | CureVac SE | Therapeutic nucleic acid for the treatment of ophthalmic diseases |
| EP4716741A2 (en) | 2023-05-23 | 2026-04-01 | Flagship Labs 114, Inc. | Compositions and methods for reducing cxcl9, cxcl10, and cxcl11 gene expression |
| AU2024279278A1 (en) | 2023-05-31 | 2025-12-18 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2024258829A1 (en) | 2023-06-12 | 2024-12-19 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025006684A1 (en) | 2023-06-28 | 2025-01-02 | Flagship Pioneering Innovations Vi, Llc | Circular polyribonucleotides encoding antifusogenic polypeptides |
| KR20260044217A (ko) | 2023-07-25 | 2026-04-01 | 플래그쉽 파이어니어링 이노베이션스 Vii, 엘엘씨 | Cas 엔도뉴클레아제 및 관련 방법 |
| WO2025042786A1 (en) | 2023-08-18 | 2025-02-27 | Flagship Pioneering Innovations Vi, Llc | Compositions comprising circular polyribonucleotides and uses thereof |
| WO2025054236A2 (en) | 2023-09-06 | 2025-03-13 | Flagship Pioneering Innovations Vii, Llc | Sars-cov-2 vaccine compositions and related methods |
| WO2025064475A2 (en) | 2023-09-18 | 2025-03-27 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| WO2025072331A1 (en) | 2023-09-26 | 2025-04-03 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025096807A2 (en) | 2023-10-31 | 2025-05-08 | Flagship Pioneering Innovations Vii, Llc | Novel therapeutic dna forms |
| WO2025106670A1 (en) | 2023-11-14 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Ionizable lipidoid compositions and therapeutic uses thereof |
| US20250161227A1 (en) | 2023-11-17 | 2025-05-22 | Acuitas Therapeutics, Inc. | Pegylated lipids |
| WO2025106930A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 2 (glp-2) and uses thereof |
| WO2025106915A1 (en) | 2023-11-17 | 2025-05-22 | Sail Biomedicines, Inc. | Circular polyribonucleotides encoding glucagon-like peptide 1 (glp-1) and uses thereof |
| US20250161347A1 (en) | 2023-11-22 | 2025-05-22 | Flagship Pioneering Innovations Vii, Llc | Methods and compositions for treating non-alcoholic fatty liver disease |
| WO2025117877A2 (en) | 2023-12-01 | 2025-06-05 | Flagship Pioneering Innovations Vii, Llc | Cas nucleases and related methods |
| WO2025128696A1 (en) | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025132122A1 (en) | 2023-12-13 | 2025-06-26 | Berlin Institute Of Health | Methods of delivering therapeutics using lipid nanoparticles |
| WO2025126071A1 (en) | 2023-12-14 | 2025-06-19 | Pfizer Inc. | Rna molecules |
| WO2025129128A1 (en) | 2023-12-15 | 2025-06-19 | Vivasor, Inc. | Compositions and methods for non-viral delivery of therapeutic compounds |
| TW202545974A (zh) | 2024-01-26 | 2025-12-01 | 美商旗艦先鋒創新有限責任（Ｖｉｉ）公司 | 免疫受體抑制蛋白及相關方法 |
| WO2025166325A1 (en) | 2024-02-02 | 2025-08-07 | Editas Medicine, Inc. | MODIFIED GUIDE RNAs |
| WO2025174858A1 (en) | 2024-02-15 | 2025-08-21 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025184508A1 (en) | 2024-03-01 | 2025-09-04 | Acuitas Therapeutics, Inc. | Materials and methods for encapsulating therapeutics in lipid nanoparticles |
| WO2025186725A2 (en) | 2024-03-06 | 2025-09-12 | Pfizer Inc. | Improved lnp formulations and uses thereof |
| WO2025194019A1 (en) | 2024-03-14 | 2025-09-18 | Flagship Pioneering Innovations Vii, Llc | Methods for treating liver fibrosis and non-alcoholic fatty liver disease |
| WO2025213138A1 (en) | 2024-04-05 | 2025-10-09 | Editas Medicine, Inc. | Crispr/rna-guided nuclease related methods and compositions for treating primary open angle glaucoma |
| WO2025217264A1 (en) | 2024-04-10 | 2025-10-16 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025217275A2 (en) | 2024-04-10 | 2025-10-16 | Flagship Pioneering Innovations Vii, Llc | Immune cell targeted compositions and related methods |
| WO2025229572A1 (en) | 2024-05-01 | 2025-11-06 | Glaxosmithkline Biologicals Sa | Epstein-barr virus antigen-encoding messenger ribonucleic acid and antigen protein vaccines |
| WO2025231114A1 (en) | 2024-05-01 | 2025-11-06 | Acuitas Therapeutics, Inc. | Method of using lipid nanoparticles for intramuscular delivery |
| US20250353881A1 (en) | 2024-05-16 | 2025-11-20 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor inhibitory proteins and related methods |
| WO2025240833A1 (en) | 2024-05-17 | 2025-11-20 | Acuitas Therapeutics, Inc. | Galnac lipid compounds for use in lipid nanoparticles |
| WO2025245188A2 (en) | 2024-05-21 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Methods of treating liver steatosis and non-alcoholic fatty liver disease |
| WO2025245111A1 (en) | 2024-05-22 | 2025-11-27 | Flagship Pioneering Innovations Vii, Llc | Immunoreceptor targeting proteins and related methods |
| US20260000702A1 (en) | 2024-06-26 | 2026-01-01 | Flagship Pioneering Innovations Vii, Llc | Therapeutic circular dna forms |
| WO2026003582A2 (en) | 2024-06-27 | 2026-01-02 | Axelyf ehf. | Lipids and lipid nanoparticles |
| WO2026018181A1 (en) | 2024-07-17 | 2026-01-22 | Pfizer Inc. | Immunogenic compositions and uses thereof |
| WO2026055543A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Modified dna compositions and related methods |
| WO2026055547A1 (en) | 2024-09-06 | 2026-03-12 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| WO2026064313A1 (en) | 2024-09-17 | 2026-03-26 | Flagship Pioneering Innovations Vii, Llc | Rna compositions and related methods |
| WO2026085300A1 (en) | 2024-10-16 | 2026-04-23 | Flagship Pioneering Innovations Vii, Llc | Compositions and methods |
Family Cites Families (430)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE707279C (de) | 1938-05-03 | 1941-06-18 | I G Farbenindustrie Akt Ges | Hochmolekulare halogenhaltige Filmbildner |
| US2411662A (en) | 1943-05-13 | 1946-11-26 | Geigy Ag J R | Imino-di-fatty acid amide |
| US2856420A (en) | 1955-12-15 | 1958-10-14 | Minnesota Mining & Mfg | Perfluoro- and perfluorochlorocarboxylic acid esters of amino alcohols |
| FR1386626A (fr) | 1963-04-02 | 1965-01-22 | Rohm & Haas | Compositions résineuses de nitrilopropionates et de polyvinyle |
| GB1030396A (en) | 1963-04-26 | 1966-05-25 | I C I Organics Inc | Bis-acyl-dialkylene triamines |
| US3340299A (en) | 1964-03-27 | 1967-09-05 | Air Reduction | Tetrasubstituted ethylene diamines |
| GB1277947A (en) | 1968-08-22 | 1972-06-14 | Armour Ind Chem Co | Compositions and method for controlling insect pests |
| US4491583A (en) * | 1970-08-07 | 1985-01-01 | Pfizer Inc. | Interferon induction in animals by amines |
| US3729564A (en) | 1970-12-16 | 1973-04-24 | Pfizer | N-secondary alkyl alkanediamines and derivatives thereof as anti-inflammatory agents |
| JPS5122416B2 (https=) | 1972-11-11 | 1976-07-09 | ||
| JPS5718088B2 (https=) | 1972-06-22 | 1982-04-14 | ||
| JPS5144547B2 (https=) | 1972-11-25 | 1976-11-29 | ||
| US3838991A (en) | 1972-12-01 | 1974-10-01 | Du Pont | Gasoline compositions containing bisamide additives |
| DE2515146A1 (de) | 1975-04-08 | 1976-10-21 | Bayer Ag | Carbonsaeureamide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
| DE2531469C3 (de) | 1975-07-15 | 1980-10-23 | Basf Ag, 6700 Ludwigshafen | Verwendung von w -N.N.N'.N'tetrasubstituierten Aminoalkansäureamiden, w -N,N,N',N'tetrasubstituierte Aminobuttersäure-amide und Verfahren zu deren Herstellung |
| DE2633615C3 (de) | 1976-07-27 | 1981-08-13 | Bayer Ag, 5090 Leverkusen | Verfahren zum Färben von synthetischen Polyamid-Fasermaterialien |
| FR2407258A1 (fr) | 1977-10-26 | 1979-05-25 | Rhone Poulenc Ind | Nouvelles compositions de carburants contenant au moins un amide d'un acide alkylpolyglycol-carboxylique derive d'alcools en c8-c20 polyoxyethyles |
| DE3010599A1 (de) | 1979-03-22 | 1980-10-09 | Continental Pharma | Derivate von glycinamid, deren herstellung und verwendung |
| EP0025083B1 (de) | 1979-09-10 | 1982-02-03 | EPROVA Aktiengesellschaft | Verfahren zur Herstellung von Serinol und Serinolderivaten |
| JPS56150002A (en) | 1980-04-23 | 1981-11-20 | Nisshin Flour Milling Co Ltd | Nonaprenylamine derivative |
| US4450282A (en) | 1981-07-29 | 1984-05-22 | General Electric Company | Catalyst for a process for producing silicones |
| US4520130A (en) | 1984-05-08 | 1985-05-28 | Scm Corporation | Halosilane catalyst and process for making same |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4883751A (en) | 1986-05-28 | 1989-11-28 | New York University | Specific immunoassay for heparin |
| US5527524A (en) | 1986-08-18 | 1996-06-18 | The Dow Chemical Company | Dense star polymer conjugates |
| US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
| US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
| US6077509A (en) | 1990-03-30 | 2000-06-20 | Autoimmune, Inc. | Peptide fragments of myelin basic protein |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
| US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
| JP2588339B2 (ja) | 1992-06-02 | 1997-03-05 | 花王株式会社 | 新規ジアミノジエステル及びその製造法 |
| US5389221A (en) | 1993-03-09 | 1995-02-14 | The University Of North Carolina At Chapel Hill | Two dimensional separation system |
| DE69534629D1 (de) | 1994-01-18 | 2005-12-29 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
| US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| JP4285766B2 (ja) | 1994-03-23 | 2009-06-24 | オハイオ ユニバーシティ | 緻密にした核酸および細胞へのデリバリ |
| US6197553B1 (en) | 1994-07-15 | 2001-03-06 | Merck & Co., Inc. | Method for large scale plasmid purification |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| USRE39229E1 (en) | 1994-08-20 | 2006-08-08 | Gendaq Limited | Binding proteins for recognition of DNA |
| FR2727679B1 (fr) | 1994-12-05 | 1997-01-03 | Rhone Poulenc Rorer Sa | Nouveaux agents de transfection et leurs applications pharmaceutiques |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US5976567A (en) | 1995-06-07 | 1999-11-02 | Inex Pharmaceuticals Corp. | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5705385A (en) | 1995-06-07 | 1998-01-06 | Inex Pharmaceuticals Corporation | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US5981501A (en) | 1995-06-07 | 1999-11-09 | Inex Pharmaceuticals Corp. | Methods for encapsulating plasmids in lipid bilayers |
| US7422902B1 (en) | 1995-06-07 | 2008-09-09 | The University Of British Columbia | Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer |
| US6020526A (en) | 1995-07-21 | 2000-02-01 | Genta, Incorporated | Amide-based cationic lipids |
| US5744335A (en) | 1995-09-19 | 1998-04-28 | Mirus Corporation | Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein |
| US5759230A (en) | 1995-11-30 | 1998-06-02 | The United States Of America As Represented By The Secretary Of The Navy | Nanostructured metallic powders and films via an alcoholic solvent process |
| JP3159029B2 (ja) | 1996-01-12 | 2001-04-23 | 信越化学工業株式会社 | シラン類の製造方法 |
| DE19605175A1 (de) | 1996-02-13 | 1997-08-14 | Sourovoi Andrej Dr | Lipidverbindungen und deren Verwendung |
| JP3792289B2 (ja) | 1996-03-26 | 2006-07-05 | 花王株式会社 | 新規第４級アンモニウム塩及びその製造方法、並びにそれを含有する毛髪化粧料 |
| JP3625102B2 (ja) | 1996-05-27 | 2005-03-02 | 富士写真フイルム株式会社 | 感熱記録材料 |
| JPH103643A (ja) | 1996-06-12 | 1998-01-06 | Fuji Photo Film Co Ltd | ディスク状磁気記録媒体 |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| KR20000049089A (ko) | 1996-10-11 | 2000-07-25 | 인피늄 홀딩스 비.브이. | 연료 조성물 |
| CA2217550A1 (en) * | 1996-10-22 | 1998-04-22 | F. Hoffmann-La Roche Ag | Cationic lipids for gene therapy |
| US6884430B1 (en) | 1997-02-10 | 2005-04-26 | Aventis Pharma S.A. | Formulation of stabilized cationic transfection agent(s) /nucleic acid particles |
| GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US5965542A (en) | 1997-03-18 | 1999-10-12 | Inex Pharmaceuticals Corp. | Use of temperature to control the size of cationic liposome/plasmid DNA complexes |
| US5756785A (en) | 1997-03-21 | 1998-05-26 | Lambent Technologies, Inc. | Guerbet betaines |
| GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| FR2763943B1 (fr) | 1997-05-28 | 1999-07-09 | Rhone Poulenc Rorer Sa | Composes, leur preparation et leur utilisation pour le transfert d'acides nucleiques dans les cellules |
| US20030073640A1 (en) | 1997-07-23 | 2003-04-17 | Ribozyme Pharmaceuticals, Inc. | Novel compositions for the delivery of negatively charged molecules |
| US6395713B1 (en) | 1997-07-23 | 2002-05-28 | Ribozyme Pharmaceuticals, Inc. | Compositions for the delivery of negatively charged molecules |
| US6989264B2 (en) | 1997-09-05 | 2006-01-24 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| WO1999033493A1 (en) | 1997-12-23 | 1999-07-08 | Inex Pharmaceuticals Corporation | Polyamide oligomers |
| US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
| US6410328B1 (en) | 1998-02-03 | 2002-06-25 | Protiva Biotherapeutics Inc. | Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| ES2341926T3 (es) | 1998-03-02 | 2010-06-29 | Massachusetts Institute Of Technology | Poliproteinas con dedos de cinc que tienen enlazadores mejorados. |
| US6986902B1 (en) | 1998-04-28 | 2006-01-17 | Inex Pharmaceuticals Corporation | Polyanionic polymers which enhance fusogenicity |
| US6013813A (en) | 1998-06-17 | 2000-01-11 | Hansotech Inc | Guerbet based sorbitan esters |
| US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
| US6333433B1 (en) | 1998-11-09 | 2001-12-25 | Council Of Scientific Industrial Research | Process for synthesis of novel cationic amphiphiles containing N-hydroxyalkl group for intracellular delivery of biologically active molecules |
| WO2000029103A1 (en) | 1998-11-13 | 2000-05-25 | Optime Therapeutics, Inc. | Method and apparatus for liposome production |
| WO2000030444A1 (en) | 1998-11-25 | 2000-06-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| US6342598B1 (en) | 1998-11-26 | 2002-01-29 | Bracco International B.V. | Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents |
| US6443610B1 (en) | 1998-12-23 | 2002-09-03 | B.E.E. International | Processing product components |
| US5919743A (en) | 1998-12-28 | 1999-07-06 | Petroferm Inc. | Guerbet branched quaternary compounds in personal care applications |
| US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
| US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
| US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
| US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
| US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
| US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
| US7112337B2 (en) | 1999-04-23 | 2006-09-26 | Alza Corporation | Liposome composition for delivery of nucleic acid |
| US6211140B1 (en) | 1999-07-26 | 2001-04-03 | The Procter & Gamble Company | Cationic charge boosting systems |
| ES2238799T3 (es) | 1999-09-09 | 2005-09-01 | Curevac Gmbh | Transferencia de arn-m. |
| AU776576B2 (en) | 1999-12-06 | 2004-09-16 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
| GB9930533D0 (en) | 1999-12-23 | 2000-02-16 | Mitsubishi Tokyo Pharm Inc | Nucleic acid delivery |
| US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US7923542B2 (en) | 2000-04-28 | 2011-04-12 | Sangamo Biosciences, Inc. | Libraries of regulatory sequences, methods of making and using same |
| ATE353361T1 (de) | 2000-04-28 | 2007-02-15 | Sangamo Biosciences Inc | Gezielten modifikation der chromatinstruktur |
| AU2001255870B2 (en) | 2000-04-28 | 2006-07-13 | Sangamo Biosciences, Inc. | Databases of regulatory sequences; methods of making and using same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| JP2001325715A (ja) | 2000-05-16 | 2001-11-22 | Sony Corp | ディスク状磁気記録媒体 |
| JP2001338416A (ja) | 2000-05-25 | 2001-12-07 | Sony Corp | ディスク状磁気記録媒体 |
| JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
| US20040142474A1 (en) | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| EP1386158B1 (de) | 2001-05-09 | 2008-05-14 | Andreas Hofmann | Gegenstand mit einer ungeladenen, funktionalisierten hydrogeloberfläche |
| DK1401869T3 (da) | 2001-06-01 | 2008-04-28 | Biogen Idec Inc | Molekyler og fremgangsmåder til inhibering af udskillkelse af kim 1 |
| JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Ｃｎｎについての亜鉛フィンガー結合ドメイン |
| JP2003081776A (ja) | 2001-09-10 | 2003-03-19 | Toho Chem Ind Co Ltd | 毛髪用処理剤 |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| WO2003042361A2 (en) | 2001-11-09 | 2003-05-22 | Government Of The United States Of America, Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
| WO2003087341A2 (en) | 2002-01-23 | 2003-10-23 | The University Of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| AU2003215869B2 (en) | 2002-03-15 | 2008-04-24 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US7074596B2 (en) | 2002-03-25 | 2006-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Synthesis and use of anti-reverse mRNA cap analogues |
| JP4111856B2 (ja) | 2002-04-12 | 2008-07-02 | 昭和電工株式会社 | 安定化されたアスコルビン酸誘導体 |
| US7419817B2 (en) | 2002-05-17 | 2008-09-02 | The United States Of America As Represented By The Secretary Department Of Health And Human Services, Nih. | Scalable purification of AAV2, AAV4 or AAV5 using ion-exchange chromatography |
| EP1519714B1 (en) | 2002-06-28 | 2010-10-20 | Protiva Biotherapeutics Inc. | Method and apparatus for producing liposomes |
| DE10229872A1 (de) | 2002-07-03 | 2004-01-29 | Curevac Gmbh | Immunstimulation durch chemisch modifizierte RNA |
| US6620794B1 (en) | 2002-07-08 | 2003-09-16 | Colonial Chemical Inc. | Guerbet functionalized phospholipids |
| US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
| EP2806025B1 (en) | 2002-09-05 | 2019-04-03 | California Institute of Technology | Use of zinc finger nucleases to stimulate gene targeting |
| EP3202899B1 (en) | 2003-01-28 | 2020-10-21 | Cellectis | Custom-made meganuclease and use thereof |
| JP4004976B2 (ja) | 2003-03-03 | 2007-11-07 | 独立行政法人科学技術振興機構 | フラーレン誘導体 |
| CA2532228C (en) | 2003-07-16 | 2017-02-14 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| DE10335833A1 (de) | 2003-08-05 | 2005-03-03 | Curevac Gmbh | Transfektion von Blutzellen mit mRNA zur Immunstimulation und Gentherapie |
| US20070134796A1 (en) | 2005-07-26 | 2007-06-14 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1664316B1 (en) | 2003-09-15 | 2012-08-29 | Protiva Biotherapeutics Inc. | Polyethyleneglycol-modified lipid compounds and uses thereof |
| US20090023718A1 (en) | 2003-11-26 | 2009-01-22 | Aton Pharma, Inc. | Diamine and Iminodiacetic Acid Hydroxamic Acid Derivatives |
| US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
| AU2005232665B2 (en) | 2004-04-08 | 2010-05-13 | Sangamo Therapeutics, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
| EP1750673B1 (en) | 2004-05-17 | 2009-12-02 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
| CA2569664C (en) | 2004-06-07 | 2013-07-16 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering rna |
| JP4764426B2 (ja) | 2004-06-07 | 2011-09-07 | プロチバ バイオセラピューティクス インコーポレイティッド | カチオン性脂質および使用方法 |
| JP4691495B2 (ja) | 2004-07-15 | 2011-06-01 | 一般財団法人化学及血清療法研究所 | コロナウイルススパイクｓ１融合蛋白及びその発現ベクター |
| DE102004042546A1 (de) | 2004-09-02 | 2006-03-09 | Curevac Gmbh | Kombinationstherapie zur Immunstimulation |
| AU2005287278B2 (en) | 2004-09-16 | 2011-08-04 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
| US8192718B1 (en) | 2005-01-04 | 2012-06-05 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| WO2007086881A2 (en) | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| US7404969B2 (en) | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| KR100699279B1 (ko) | 2005-04-28 | 2007-03-23 | 학교법인 포항공과대학교 | 당 또는 당 유사체를 골격으로 하는 분자 수송체 및 그의제조방법 |
| CA2607104A1 (en) | 2005-05-05 | 2006-11-16 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
| WO2006138380A2 (en) | 2005-06-15 | 2006-12-28 | Massachusetts Institute Of Technology | Amine-containing lipids and uses thereof |
| CN101267805A (zh) | 2005-07-27 | 2008-09-17 | 普洛体维生物治疗公司 | 制造脂质体的系统和方法 |
| PL2578685T3 (pl) | 2005-08-23 | 2020-01-31 | The Trustees Of The University Of Pennsylvania | Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania |
| US7443760B2 (en) | 2005-09-29 | 2008-10-28 | Hynix Semiconductor Inc. | Multi-port memory device with serial input/output interface |
| ES2582091T3 (es) | 2005-10-18 | 2016-09-09 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| JP4681425B2 (ja) | 2005-11-15 | 2011-05-11 | 花王株式会社 | 毛髪弾性改善剤 |
| ES2465996T3 (es) | 2006-05-25 | 2014-06-09 | Sangamo Biosciences, Inc. | Métodos y composiciones para la inactivación genética |
| EP2027262B1 (en) | 2006-05-25 | 2010-03-31 | Sangamo Biosciences Inc. | Variant foki cleavage half-domains |
| DE102006035618A1 (de) | 2006-07-31 | 2008-02-07 | Curevac Gmbh | Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz |
| CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
| DE102007001370A1 (de) | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| CA2689042A1 (en) | 2007-02-16 | 2008-08-28 | Merck & Co., Inc. | Compositions and methods for potentiated activity of biologicaly active molecules |
| DE602008003684D1 (de) | 2007-04-26 | 2011-01-05 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
| CN104072561B (zh) | 2007-06-19 | 2017-12-22 | 路易斯安那州州立大学及农业机械学院管理委员会 | 信使rna帽的抗‑反向硫代磷酸类似物的合成和用途 |
| WO2009030254A1 (en) | 2007-09-04 | 2009-03-12 | Curevac Gmbh | Complexes of rna and cationic peptides for transfection and for immunostimulation |
| US8563314B2 (en) | 2007-09-27 | 2013-10-22 | Sangamo Biosciences, Inc. | Methods and compositions for modulating PD1 |
| MX2010003371A (es) | 2007-09-28 | 2010-05-05 | Intrexon Corp | Constructos interruptores genicos terapeuticos y biorreactores para la expresion de moleculas bioterapeuticas y usos de los mismos. |
| EP2436376B1 (en) | 2007-09-28 | 2014-07-09 | BIND Therapeutics, Inc. | Cancer cell targeting using nanoparticles |
| WO2009046738A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating lung cancer, particularly of non-small lung cancers (nsclc) |
| WO2009046739A1 (en) | 2007-10-09 | 2009-04-16 | Curevac Gmbh | Composition for treating prostate cancer (pca) |
| WO2009073809A2 (en) | 2007-12-04 | 2009-06-11 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
| WO2009088891A1 (en) | 2008-01-02 | 2009-07-16 | Alnylam Pharmaceuticals, Inc. | Screening method for selected amino lipid-containing compositions |
| CA2711240C (en) | 2008-01-02 | 2021-10-26 | Alnylam Pharmaceuticals, Inc. | Liver screening method |
| WO2009086558A1 (en) | 2008-01-02 | 2009-07-09 | Tekmira Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
| DK2176408T5 (en) | 2008-01-31 | 2015-12-14 | Curevac Gmbh | Nucleic acids comprising FORMULA (NuGiXmGnNv) a AND DERIVATIVES AS IMMUNE STIMULATING AGENTS / ADJUVANTS. |
| PL210199B1 (pl) | 2008-02-18 | 2011-12-30 | Politechnika Wroclawska | Nowe długołańcuchowe diamidoaminy pochodne kwasu propionowego i sposób ich wytwarzania |
| KR100934125B1 (ko) | 2008-02-27 | 2009-12-29 | 포항공과대학교 산학협력단 | 브러쉬 고분자 화합물, 이의 제조방법 및 이를 이용한화학센서 소자 |
| CA2721183C (en) | 2008-04-11 | 2019-07-16 | Alnylam Pharmaceuticals, Inc. | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| CA2720903C (en) | 2008-04-14 | 2019-01-15 | Sangamo Biosciences, Inc. | Linear donor constructs for targeted integration |
| CA2721333C (en) | 2008-04-15 | 2020-12-01 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for nucleic acid delivery |
| US20090285881A1 (en) | 2008-04-16 | 2009-11-19 | Abbott Laboratories | Cationic lipids and uses thereof |
| US20090263407A1 (en) | 2008-04-16 | 2009-10-22 | Abbott Laboratories | Cationic Lipids and Uses Thereof |
| WO2009132131A1 (en) | 2008-04-22 | 2009-10-29 | Alnylam Pharmaceuticals, Inc. | Amino lipid based improved lipid formulation |
| WO2009151591A2 (en) | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
| US8318211B2 (en) | 2008-06-16 | 2012-11-27 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same |
| EA020954B1 (ru) | 2008-06-16 | 2015-03-31 | Бинд Терапьютикс, Инк. | Загруженные лекарственным средством полимерные наночастицы, фармацевтическая композиция и способ лечения рака |
| JP2011525180A (ja) | 2008-06-16 | 2011-09-15 | バインド バイオサイエンシズ インコーポレイテッド | 治療的標的化ナノ粒子の製作に用いるためのジブロックコポリマーで官能化された標的薬の製造方法 |
| WO2010005726A2 (en) | 2008-06-16 | 2010-01-14 | Bind Biosciences Inc. | Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same |
| WO2010021865A1 (en) | 2008-08-18 | 2010-02-25 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| SG191561A1 (en) | 2008-08-22 | 2013-07-31 | Sangamo Biosciences Inc | Methods and compositions for targeted single-stranded cleavage and targeted integration |
| US20100087337A1 (en) | 2008-09-10 | 2010-04-08 | Bind Biosciences, Inc. | High Throughput Fabrication of Nanoparticles |
| PL217831B1 (pl) | 2008-09-22 | 2014-08-29 | Inst Chemii Organicznej Polska Akademia Nauk | Związki dendrymeryczne zawierające aminokwasy, wysokorozgałęziony związek rdzeniowy, sposób wytwarzania związków dendrymerycznych zawierających aminokwasy i wysokorozgałęzionego związku rdzeniowego oraz ich zastosowanie |
| WO2010037408A1 (en) | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
| WO2010048536A2 (en) | 2008-10-23 | 2010-04-29 | Alnylam Pharmaceuticals, Inc. | Processes for preparing lipids |
| WO2010062322A2 (en) | 2008-10-27 | 2010-06-03 | Massachusetts Institute Of Technology | Modulation of the immune response |
| CN111808084A (zh) | 2008-11-10 | 2020-10-23 | 阿布特斯生物制药公司 | 用于递送治疗剂的新型脂质和组合物 |
| US8722082B2 (en) | 2008-11-10 | 2014-05-13 | Tekmira Pharmaceuticals Corporation | Lipids and compositions for the delivery of therapeutics |
| CA2742838A1 (en) | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable polymeric lipids for nucleic acids delivery systems |
| EP2352369B1 (en) | 2008-12-04 | 2017-04-26 | Sangamo BioSciences, Inc. | Genome editing in rats using zinc-finger nucleases |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2010080724A1 (en) | 2009-01-12 | 2010-07-15 | Merck Sharp & Dohme Corp. | Novel lipid nanoparticles and novel components for delivery of nucleic acids |
| EP3243504A1 (en) | 2009-01-29 | 2017-11-15 | Arbutus Biopharma Corporation | Improved lipid formulation |
| SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
| CA3045126A1 (en) | 2009-05-05 | 2010-11-11 | Arbutus Biopharma Corporation | Methods of delivering oligonucleotides to immune cells |
| KR101766408B1 (ko) | 2009-06-10 | 2017-08-10 | 알닐람 파마슈티칼스 인코포레이티드 | 향상된 지질 조성물 |
| US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
| US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| WO2011000107A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Novel lipid formulations for delivery of therapeutic agents to solid tumors |
| US8569256B2 (en) | 2009-07-01 | 2013-10-29 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
| CA2769262C (en) | 2009-07-28 | 2019-04-30 | Sangamo Biosciences, Inc. | Methods and compositions for treating trinucleotide repeat disorders |
| CA2769670C (en) | 2009-07-31 | 2018-10-02 | Ethris Gmbh | Rna with a combination of unmodified and modified nucleotides for protein expression |
| US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
| ES2579936T3 (es) | 2009-08-20 | 2016-08-17 | Sirna Therapeutics, Inc. | Nuevos lípidos catiónicos con diversos grupos de cabeza para el suministro oligonucleotídico |
| WO2011036557A1 (en) | 2009-09-22 | 2011-03-31 | The University Of British Columbia | Compositions and methods for enhancing cellular uptake and intracellular delivery of lipid particles |
| EP2485770A4 (en) | 2009-10-08 | 2013-04-10 | Merck Sharp & Dohme | Novel cationic lipids with short lipid chains for oligonucleotide delivery |
| CN107028886A (zh) | 2009-11-04 | 2017-08-11 | 不列颠哥伦比亚大学 | 含有核酸的脂质粒子及相关的方法 |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| WO2011066651A1 (en) | 2009-12-01 | 2011-06-09 | Protiva Biotherapeutics, Inc. | Snalp formulations containing antioxidants |
| EP3296398A1 (en) | 2009-12-07 | 2018-03-21 | Arbutus Biopharma Corporation | Compositions for nucleic acid delivery |
| WO2011072246A2 (en) | 2009-12-10 | 2011-06-16 | Regents Of The University Of Minnesota | Tal effector-mediated dna modification |
| EP2515942B1 (en) | 2009-12-15 | 2020-02-12 | Pfizer Inc. | Therapeutic polymeric nanoparticle compositions with high glass transition temperature or high molecular weight copolymers |
| WO2011084521A2 (en) | 2009-12-15 | 2011-07-14 | Bind Biosciences, Inc. | Therapeutic polymeric nanoparticles comprising epothilone and methods of making and using same |
| EP3494963A1 (en) | 2009-12-18 | 2019-06-12 | The University of British Columbia | Methods and compositions for delivery of nucleic acids |
| CA3009891C (en) | 2009-12-23 | 2020-09-15 | Novartis Ag | Lipids, lipid compositions, and methods of using them |
| EP2525781A1 (en) | 2010-01-22 | 2012-11-28 | Schering Corporation | Novel cationic lipids for oligonucleotide delivery |
| WO2011094198A1 (en) | 2010-01-28 | 2011-08-04 | The Children's Hospital Of Philadelphia Research Institute, Abramson Research Center | A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy |
| ES2751916T3 (es) | 2010-02-08 | 2020-04-02 | Sangamo Therapeutics Inc | Semidominios de escisión genomanipulados |
| EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
| US20130190327A1 (en) | 2010-02-26 | 2013-07-25 | Catabasis Pharmaceuticals Inc | Bis-fatty acid conjugates and their uses |
| US9149432B2 (en) | 2010-03-19 | 2015-10-06 | Massachusetts Institute Of Technology | Lipid vesicle compositions and methods of use |
| US20130037977A1 (en) | 2010-04-08 | 2013-02-14 | Paul A. Burke | Preparation of Lipid Nanoparticles |
| US20110262491A1 (en) | 2010-04-12 | 2011-10-27 | Selecta Biosciences, Inc. | Emulsions and methods of making nanocarriers |
| US9567573B2 (en) | 2010-04-26 | 2017-02-14 | Sangamo Biosciences, Inc. | Genome editing of a Rosa locus using nucleases |
| KR101773643B1 (ko) | 2010-04-28 | 2017-08-31 | 교와 핫꼬 기린 가부시키가이샤 | 양이온성 지질 |
| WO2011136369A1 (ja) | 2010-04-28 | 2011-11-03 | 協和発酵キリン株式会社 | カチオン性脂質 |
| HRP20200254T1 (hr) | 2010-05-03 | 2020-05-29 | Sangamo Therapeutics, Inc. | Pripravci za povezivanje modula cink fingera |
| WO2011143230A1 (en) | 2010-05-10 | 2011-11-17 | Alnylam Pharmaceuticals | Methods and compositions for delivery of active agents |
| WO2011141703A1 (en) | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
| US20130123338A1 (en) | 2010-05-12 | 2013-05-16 | Protiva Biotherapeutics, Inc. | Novel cationic lipids and methods of use thereof |
| US8802863B2 (en) | 2010-05-24 | 2014-08-12 | Sirna Therapeutics, Inc. | Amino alcohol cationic lipids for oligonucleotide delivery |
| KR20190039347A (ko) | 2010-06-03 | 2019-04-10 | 알닐람 파마슈티칼스 인코포레이티드 | 활성제의 전달을 위한 생분해성 지질 |
| DK2575767T3 (en) | 2010-06-04 | 2017-03-13 | Sirna Therapeutics Inc | HOWEVER UNKNOWN LOW MOLECULAR CATIONIC LIPIDS TO PROCESS OIGONUCLEOTIDES |
| US9006417B2 (en) | 2010-06-30 | 2015-04-14 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| ES2557382T3 (es) | 2010-07-06 | 2016-01-25 | Glaxosmithkline Biologicals Sa | Liposomas con lípidos que tienen un valor de pKa ventajoso para el suministro de ARN |
| AU2011281062B2 (en) | 2010-07-21 | 2015-01-22 | Board Of Regents, The University Of Texas System | Methods and compositions for modification of a HLA locus |
| WO2012016184A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012019630A1 (en) | 2010-08-13 | 2012-02-16 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein |
| MX2013002332A (es) | 2010-08-31 | 2013-03-18 | Novartis Ag | Lipidos apropiados para suministro liposomal del arn que codifica la proteina. |
| SI4043040T1 (sl) | 2010-08-31 | 2023-04-28 | Glaxosmithkline Biologicals Sa | Mali liposomi za dostavo imunogen-kodirajoče RNA |
| LT4226941T (lt) | 2010-08-31 | 2025-01-10 | Glaxosmithkline Biologicals Sa | Pegilintos liposomos, skirtos imunogeną koduojančios rnr pristatymui |
| US8466122B2 (en) | 2010-09-17 | 2013-06-18 | Protiva Biotherapeutics, Inc. | Trialkyl cationic lipids and methods of use thereof |
| CA2809858C (en) | 2010-09-20 | 2019-11-12 | Sirna Therapeutics, Inc. | Novel low molecular weight cationic lipids for oligonucleotide delivery |
| CA2811430A1 (en) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Low molecular weight cationic lipids for oligonucleotide delivery |
| WO2012054743A2 (en) | 2010-10-20 | 2012-04-26 | Yongquan Xue | Taste modifying compositions |
| EP3485913A1 (en) | 2010-10-21 | 2019-05-22 | Sirna Therapeutics, Inc. | Low molecular weight cationic lipids for oligonucleotide delivery |
| US20150056300A1 (en) | 2010-10-22 | 2015-02-26 | Bind Therapeutics, Inc. | Therapeutic nanoparticles with high molecular weight copolymers |
| WO2012061259A2 (en) | 2010-11-05 | 2012-05-10 | Merck Sharp & Dohme Corp. | Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery |
| CN103380113B (zh) | 2010-11-15 | 2018-03-30 | 生命科技公司 | 含胺的转染试剂及其制备和使用方法 |
| WO2012089225A1 (en) | 2010-12-29 | 2012-07-05 | Curevac Gmbh | Combination of vaccination and inhibition of mhc class i restricted antigen presentation |
| WO2012116715A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in newborns and infants |
| WO2012113413A1 (en) | 2011-02-21 | 2012-08-30 | Curevac Gmbh | Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
| WO2012133737A1 (ja) | 2011-03-31 | 2012-10-04 | 公益財団法人地球環境産業技術研究機構 | 架橋性アミン化合物、該化合物を用いた高分子膜及びその製造方法 |
| US8691750B2 (en) | 2011-05-17 | 2014-04-08 | Axolabs Gmbh | Lipids and compositions for intracellular delivery of biologically active compounds |
| WO2013014073A1 (en) | 2011-07-22 | 2013-01-31 | Universite De Strasbourg | Phospholipid-detergent conjugates and uses thereof |
| WO2013016058A1 (en) | 2011-07-22 | 2013-01-31 | Merck Sharp & Dohme Corp. | Novel bis-nitrogen containing cationic lipids for oligonucleotide delivery |
| US9126966B2 (en) | 2011-08-31 | 2015-09-08 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use thereof |
| CA2848417C (en) | 2011-09-21 | 2023-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of transgene expression |
| EP3456317B1 (en) | 2011-09-27 | 2025-09-24 | Alnylam Pharmaceuticals, Inc. | Di-aliphatic substituted pegylated lipids |
| CN107266391B (zh) | 2011-10-18 | 2020-04-17 | 迪克纳制药公司 | 胺阳离子脂质及其用途 |
| CA3099582A1 (en) | 2011-10-27 | 2013-05-02 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
| PE20181541A1 (es) | 2011-10-27 | 2018-09-26 | Massachusetts Inst Technology | Derivados de aminoacidos funcionalizados en la terminal n capaces de formar microesferas encapsuladoras de farmaco |
| JP2013095755A (ja) | 2011-11-02 | 2013-05-20 | Kyowa Hakko Kirin Co Ltd | カチオン性脂質 |
| EP3485875A1 (en) | 2011-11-04 | 2019-05-22 | Nitto Denko Corporation | Single use system for sterelily producing lipid-nucleic acid particles |
| HK1200871A1 (en) | 2011-11-16 | 2015-08-14 | Sangamo Therapeutics, Inc. | Modified dna-binding proteins and uses thereof |
| AU2012347605B2 (en) | 2011-12-07 | 2017-09-21 | Alnylam Pharmaceuticals, Inc. | Branched alkyl and cycloalkyl terminated biodegradable lipids for the delivery of active agents |
| WO2013086354A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Biodegradable lipids for the delivery of active agents |
| WO2013086373A1 (en) | 2011-12-07 | 2013-06-13 | Alnylam Pharmaceuticals, Inc. | Lipids for the delivery of active agents |
| KR20140111272A (ko) | 2011-12-12 | 2014-09-18 | 교와 핫꼬 기린 가부시키가이샤 | 양이온성 지질의 조합을 함유하는 지질 나노 입자 |
| CA3018046A1 (en) | 2011-12-16 | 2013-06-20 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
| WO2013113325A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Negatively charged nucleic acid comprising complexes for immunostimulation |
| WO2013113326A1 (en) | 2012-01-31 | 2013-08-08 | Curevac Gmbh | Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen |
| EP2623121A1 (en) | 2012-01-31 | 2013-08-07 | Bayer Innovation GmbH | Pharmaceutical composition comprising a polymeric carrier cargo complex and an antigen |
| WO2013120498A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen |
| WO2013120497A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein |
| WO2013120499A1 (en) | 2012-02-15 | 2013-08-22 | Curevac Gmbh | Nucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen |
| CN102604115B (zh) | 2012-02-22 | 2013-07-10 | 天津大学 | 羧甲基壳聚糖季铵盐/pamam核壳纳米粒及制备方法 |
| EP2817287B1 (en) | 2012-02-24 | 2018-10-03 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| MX362981B (es) | 2012-03-27 | 2019-02-28 | Curevac Ag | Moleculas artificiales de acido nucleico para la expresion mejorada de proteina o peptido. |
| WO2013143700A2 (en) | 2012-03-27 | 2013-10-03 | Curevac Gmbh | Artificial nucleic acid molecules comprising a 5'top utr |
| SG11201405542UA (en) | 2012-03-27 | 2014-10-30 | Curevac Gmbh | Artificial nucleic acid molecules |
| AU2013240051B2 (en) | 2012-03-27 | 2017-11-30 | Sirna Therapeutics, Inc. | Diether based biodegradable cationic lipids for siRNA delivery |
| EP2852380A4 (en) | 2012-05-23 | 2016-01-20 | Univ Ohio State | LIPID-COATED ALBUMIN NANOPARTICLE COMPOSITIONS AND METHOD FOR THE PREPARATION AND METHOD OF USE THEREOF |
| WO2013174409A1 (en) | 2012-05-25 | 2013-11-28 | Curevac Gmbh | Reversible immobilization and/or controlled release of nucleic acid containing nanoparticles by (biodegradable) polymer coatings |
| TW201408625A (zh) | 2012-07-06 | 2014-03-01 | Kyowa Hakko Kirin Co Ltd | 陽離子性脂質 |
| WO2014008334A1 (en) | 2012-07-06 | 2014-01-09 | Alnylam Pharmaceuticals, Inc. | Stable non-aggregating nucleic acid lipid particle formulations |
| EP3196301B1 (en) | 2012-07-11 | 2018-10-17 | Sangamo Therapeutics, Inc. | Methods and compositions for the treatment of monogenic diseases |
| WO2014028487A1 (en) | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| EP2711076A3 (en) | 2012-09-21 | 2016-05-25 | Total Synthesis Ltd. | Fluid processing apparatus |
| AU2013329186B2 (en) | 2012-10-10 | 2019-02-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
| US9255250B2 (en) | 2012-12-05 | 2016-02-09 | Sangamo Bioscience, Inc. | Isolated mouse or human cell having an exogenous transgene in an endogenous albumin gene |
| WO2014089239A1 (en) | 2012-12-07 | 2014-06-12 | Alnylam Pharmaceuticals, Inc. | Improved nucleic acid lipid particle formulations |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| US9974845B2 (en) | 2013-02-22 | 2018-05-22 | Curevac Ag | Combination of vaccination and inhibition of the PD-1 pathway |
| CN107879960B (zh) | 2013-03-08 | 2021-06-22 | 诺华股份有限公司 | 用于传递活性成分的脂质和脂质组合物 |
| WO2014160284A1 (en) | 2013-03-14 | 2014-10-02 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of stroke |
| US20160032316A1 (en) | 2013-03-14 | 2016-02-04 | The Trustees Of The University Of Pennsylvania | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides |
| CN105142614A (zh) | 2013-03-14 | 2015-12-09 | 迪克纳制药公司 | 用于配制阴离子试剂的方法 |
| CN105683376A (zh) | 2013-05-15 | 2016-06-15 | 桑格摩生物科学股份有限公司 | 用于治疗遗传病状的方法和组合物 |
| WO2014191467A1 (en) | 2013-05-30 | 2014-12-04 | Bracco Imaging Spa | Fluorescent solid lipid nanoparticles composition and preparation thereof |
| JP6620093B2 (ja) | 2013-07-23 | 2019-12-11 | アービュートゥス バイオファーマ コーポレイションＡｒｂｕｔｕｓ Ｂｉｏｐｈａｒｍａ Ｃｏｒｐｏｒａｔｉｏｎ | メッセンジャーｒｎａを送達するための組成物及び方法 |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| BR112016003361A2 (pt) | 2013-08-21 | 2017-11-21 | Curevac Ag | vacina do vírus sincicial respiratório (rsv) |
| AU2014310935B2 (en) | 2013-08-21 | 2019-11-21 | CureVac SE | Combination vaccine |
| RU2016109938A (ru) | 2013-08-21 | 2017-09-26 | Куревак Аг | Композиция и вакцина для лечения рака предстательной железы |
| BR112016001192A2 (pt) | 2013-08-21 | 2017-08-29 | Curevac Ag | Vacina contra a raiva |
| US10195291B2 (en) | 2013-09-24 | 2019-02-05 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for the manufacture of lipid nanoparticles |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| AU2014348212C1 (en) | 2013-11-18 | 2018-11-29 | Arcturus Therapeutics, Inc. | Ionizable cationic lipid for RNA delivery |
| EP3071236A4 (en) | 2013-11-20 | 2017-05-24 | Trustees of Boston University | Injectable tissue supplement |
| CN105940013B (zh) | 2013-12-09 | 2020-03-27 | 桑格摩生物科学股份有限公司 | 用于治疗血友病的方法和组合物 |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| WO2015123576A2 (en) | 2014-02-17 | 2015-08-20 | The Brigham And Women's Hospital, Inc. | Targeted nanoparticle compositions and methods of their use to treat obesity |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| US10369216B2 (en) | 2014-04-01 | 2019-08-06 | Curevac Ag | Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant |
| US10406059B2 (en) | 2014-04-21 | 2019-09-10 | The Trustees Of Columbia University In The City Of New York | Human movement research, therapeutic, and diagnostic devices, methods, and systems |
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| WO2015171932A1 (en) | 2014-05-08 | 2015-11-12 | Sangamo Biosciences, Inc. | Methods and compositions for treating huntington's disease |
| JP6478775B2 (ja) | 2014-05-15 | 2019-03-06 | キヤノン株式会社 | アミン化合物及びイオン導電剤、導電性樹脂組成物 |
| EP3146221B1 (en) | 2014-05-22 | 2019-05-08 | Flowserve S.r.l. | Guide element for a valve actuator and actuator provided with said guide element |
| WO2015183290A1 (en) | 2014-05-29 | 2015-12-03 | Agilent Technologies, Inc. | Apparatus and method for introducing a sample into a separation unit of a chromatography system |
| HUE060907T2 (hu) | 2014-06-25 | 2023-04-28 | Acuitas Therapeutics Inc | Új lipidek és lipid nanorészecske formulációk nukleinsavak bevitelére |
| CN106794141B (zh) | 2014-07-16 | 2021-05-28 | 诺华股份有限公司 | 将核酸包封在脂质纳米粒主体中的方法 |
| JP6339884B2 (ja) | 2014-07-17 | 2018-06-06 | 富士フイルム株式会社 | イミダゾール化合物およびそれを含有するリポソーム |
| PL3172202T3 (pl) | 2014-07-22 | 2020-07-13 | Boehringer Ingelheim International Gmbh | Heterocykliczne kwasy karboksylowe jako aktywatory rozpuszczalnej cyklazy guanylanowej |
| WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
| WO2016071857A1 (en) | 2014-11-07 | 2016-05-12 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus expression |
| PT4023755T (pt) | 2014-12-12 | 2023-07-05 | CureVac SE | Moléculas de ácido nucleico artificiais para uma expressão melhorada de proteína |
| EP3233113A1 (en) | 2014-12-16 | 2017-10-25 | CureVac AG | Ebolavirus and marburgvirus vaccines |
| EP3240558A1 (en) | 2014-12-30 | 2017-11-08 | CureVac AG | Artificial nucleic acid molecules |
| JP2018509387A (ja) | 2015-01-21 | 2018-04-05 | フェーズアールエックス インコーポレイテッド | 細胞に治療および診断剤を送達するための方法、組成物、ならびにシステム |
| WO2016138175A1 (en) | 2015-02-24 | 2016-09-01 | The University Of British Columbia | Continuous flow microfluidic system |
| EP3278099B1 (en) | 2015-03-31 | 2025-09-10 | Waters Technologies Corporation | Multi-injection mode valve module |
| CN104876831B (zh) | 2015-04-03 | 2017-05-17 | 苏州圣诺生物医药技术有限公司 | 脂质修饰精胺衍生物及利用该衍生物制备的脂质体 |
| EP4353257A3 (en) | 2015-04-13 | 2024-08-07 | CureVac Manufacturing GmbH | Method for producing rna compositions |
| WO2016168469A1 (en) | 2015-04-17 | 2016-10-20 | The Regents Of The University Of California | Fatty acid analogs and methods of use thereof |
| AU2016253972B2 (en) | 2015-04-27 | 2020-01-02 | Acuitas Therapeutics Inc. | Nucleoside-modified RNA for inducing an adaptive immune response |
| US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
| AU2016261927B2 (en) | 2015-05-12 | 2022-04-07 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
| WO2016184822A1 (en) | 2015-05-15 | 2016-11-24 | Curevac Ag | Prime-boost regimens involving administration of at least one mrna construct |
| US20180296663A1 (en) | 2015-06-17 | 2018-10-18 | Curevac Ag | Vaccine composition |
| US10167253B2 (en) | 2015-06-24 | 2019-01-01 | Nitto Denko Corporation | Ionizable compounds and compositions and uses thereof |
| PT3313829T (pt) | 2015-06-29 | 2024-07-08 | Acuitas Therapeutics Inc | Formulações de lípidos e de nanopartículas lipídicas para a administração de ácidos nucleicos |
| EP3320328B1 (en) | 2015-07-10 | 2021-03-17 | Molecular Devices, LLC | Single injection competitive binding assays |
| US20200085852A1 (en) | 2015-08-05 | 2020-03-19 | Curevac Ag | Epidermal mrna vaccine |
| WO2017025120A1 (en) | 2015-08-07 | 2017-02-16 | Curevac Ag | Process for the in vivo production of rna in a host cell |
| WO2017036580A1 (en) | 2015-08-28 | 2017-03-09 | Curevac Ag | Artificial nucleic acid molecules |
| WO2017048770A1 (en) | 2015-09-15 | 2017-03-23 | Regulus Therapeutics, Inc. | Systems, compositions, and methods for formulating nucleic acid compositions |
| JP6948313B6 (ja) | 2015-09-17 | 2022-01-14 | モデルナティエックス インコーポレイテッド | 治療剤の細胞内送達のための化合物および組成物 |
| US11225682B2 (en) | 2015-10-12 | 2022-01-18 | Curevac Ag | Automated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution |
| AU2016342376A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Sexually transmitted disease vaccines |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| MY189674A (en) | 2015-10-28 | 2022-02-24 | Sangamo Therapeutics Inc | Liver-specific constructs, factor viii expression cassettes and methods of use thereof |
| HRP20230209T1 (hr) | 2015-10-28 | 2023-04-14 | Acuitas Therapeutics Inc. | Novi lipidi i lipidne formulacije nanočestica za isporuku nukleinskih kiselina |
| EP3374504B1 (en) | 2015-11-09 | 2025-03-19 | CureVac SE | Optimized nucleic acid molecules |
| EP3373965A1 (en) | 2015-11-09 | 2018-09-19 | CureVac AG | Rotavirus vaccines |
| CN105343891A (zh) | 2015-11-19 | 2016-02-24 | 苏州桓晨医疗科技有限公司 | 聚电解质复合物及其用途 |
| MA43568A (fr) | 2015-12-17 | 2018-11-14 | Modernatx Inc | Polynucléotides codant pour la méthylmalonyl-coa mutase |
| EP3389677B1 (en) | 2015-12-18 | 2024-06-26 | Sangamo Therapeutics, Inc. | Targeted disruption of the t cell receptor |
| BR112018012235A2 (pt) | 2015-12-18 | 2018-12-04 | Sangamo Therapeutics Inc | rompimento alvejado do receptor de células de mhc |
| LT3394030T (lt) | 2015-12-22 | 2022-04-11 | Modernatx, Inc. | Junginiai ir kompozicijos terapinei medžiagai teikti intraceliuliniu būdu |
| WO2017117528A1 (en) | 2015-12-30 | 2017-07-06 | Acuitas Therapeutics, Inc. | Lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| SG10201913630YA (en) | 2016-02-17 | 2020-03-30 | Curevac Ag | Zika virus vaccine |
| US10583432B2 (en) | 2016-02-29 | 2020-03-10 | Michael Organ | Non-disruptive sampler for fluid processing apparatus |
| US20170266292A1 (en) | 2016-03-21 | 2017-09-21 | The Research Foundation For The State University Of New York | Lipidic compound-telodendrimer hybrid nanoparticles and methods of making and uses thereof |
| LT3436077T (lt) | 2016-03-30 | 2025-06-25 | Intellia Therapeutics, Inc. | Lipidų nanodalelių vaisto formos, skirtos crispr/cas komponentams |
| EP3445392A1 (en) | 2016-04-22 | 2019-02-27 | CureVac AG | Rna encoding a tumor antigen |
| US20180126003A1 (en) | 2016-05-04 | 2018-05-10 | Curevac Ag | New targets for rna therapeutics |
| US11458106B2 (en) | 2016-05-09 | 2022-10-04 | Astrazeneca Ab | Lipid nanoparticles comprising lipophilic anti-inflammatory agents and methods of use thereof |
| MA45036A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour la citrine pour le traitement de la citrullinémie de type 2 |
| US20190298657A1 (en) | 2016-05-18 | 2019-10-03 | Modernatx, Inc. | Polynucleotides Encoding Acyl-CoA Dehydrogenase, Very Long-Chain for the Treatment of Very Long-Chain Acyl-CoA Dehydrogenase Deficiency |
| KR102455249B1 (ko) | 2016-08-24 | 2022-10-17 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
| CA3035534A1 (en) | 2016-09-07 | 2018-03-15 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
| CA3040337A1 (en) | 2016-10-26 | 2018-05-03 | Curevac Ag | Lipid nanoparticle mrna vaccines |
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| EP3532103B1 (en) | 2016-10-26 | 2025-12-03 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| US20190274968A1 (en) | 2016-10-27 | 2019-09-12 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| AU2017356699B2 (en) | 2016-11-08 | 2021-11-11 | Ramot At Tel-Aviv University Ltd. | Cationic lipids for nucleic acid delivery and preparation thereof |
| AU2017374042C1 (en) | 2016-12-09 | 2024-07-11 | Acuitas Therapeutics, Inc. | Delivery of target specific nucleases |
| CA3049991A1 (en) | 2017-01-11 | 2018-07-19 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an immune response against zika virus |
| WO2018191657A1 (en) * | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipids for delivery of active agents |
| WO2018191719A1 (en) | 2017-04-13 | 2018-10-18 | Acuitas Therapeutics, Inc. | Lipid delivery of therapeutic agents to adipose tissue |
| CN110799492B (zh) | 2017-04-28 | 2023-06-27 | 爱康泰生治疗公司 | 用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂 |
| US20210008552A1 (en) | 2017-06-15 | 2021-01-14 | Lexagene, Inc. | Nucleic acid extraction and purification cartridges |
| WO2019027999A1 (en) | 2017-07-31 | 2019-02-07 | Ohio State Innovation Foundation | BIOMIMETIC NANOMATERIALS AND USES THEREOF |
| CA3073020A1 (en) | 2017-08-16 | 2019-02-21 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| WO2019036028A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICULAR FORMULATIONS |
| WO2019036030A1 (en) | 2017-08-17 | 2019-02-21 | Acuitas Therapeutics, Inc. | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS |
| EP4501322A3 (en) | 2017-08-17 | 2025-04-16 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| EP3688161A1 (en) | 2017-09-29 | 2020-08-05 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis |
| US20230140670A1 (en) | 2017-09-29 | 2023-05-04 | Intellia Therapeutics, Inc. | Formulations |
| WO2019089828A1 (en) | 2017-10-31 | 2019-05-09 | Acuitas Therapeutics, Inc. | Lamellar lipid nanoparticles |
| MX2020007944A (es) | 2018-02-01 | 2020-11-24 | Tufts College | Nanocomplejos similares a los lípidos y sus usos. |
| US20200093936A1 (en) | 2018-09-21 | 2020-03-26 | The Trustees Of The University Of Pennsylvania | Therapeutic Targeting of Lipid Nanoparticles |
| IL281615B2 (en) | 2018-09-21 | 2026-01-01 | Acuitas Therapeutics Inc | Systems and methods for producing lipid nanoparticles and liposomes |
| PT3908568T (pt) | 2019-01-11 | 2024-09-30 | Acuitas Therapeutics Inc | Lípidos para a administração de agentes ativos por nanopartículas lipídicas |
| JP7631215B2 (ja) | 2019-03-28 | 2025-02-18 | インテリア セラピューティクス，インコーポレイテッド | Ｔｔｒガイドｒｎａと、ｒｎａガイドｄｎａ結合剤をコードするポリヌクレオチドとを含む組成物および方法 |
| CN114901253A (zh) | 2019-08-14 | 2022-08-12 | 爱康泰生治疗公司 | 用于递送核酸的改进的脂质纳米颗粒 |
| AU2020350759A1 (en) | 2019-09-19 | 2022-03-31 | Modernatx, Inc. | Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents |
| US20240122854A1 (en) | 2019-11-27 | 2024-04-18 | Acuitas Therapeutics, Inc. | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| JP7340449B2 (ja) | 2019-12-31 | 2023-09-07 | 株式会社クボタ | Ｅｇｒ付エンジン用排気マニホルド |
| WO2021204175A1 (en) | 2020-04-09 | 2021-10-14 | Suzhou Abogen Biosciences Co., Ltd. | Lipid nanoparticle composition |
| ES3054438T3 (en) | 2020-07-16 | 2026-02-03 | Acuitas Therapeutics Inc | Cationic lipids for use in lipid nanoparticles |
| CN115515925B (zh) | 2021-04-08 | 2024-10-11 | 厦门赛诺邦格生物科技股份有限公司 | 一种聚乙二醇化脂质及其修饰的脂质体、含该脂质体的药物组合物及其制剂和应用 |
| CN113402404B (zh) | 2021-04-30 | 2022-03-11 | 苏州科锐迈德生物医药科技有限公司 | 脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| CN113387825A (zh) | 2021-06-10 | 2021-09-14 | 福州大学 | 长链烷基酯胺类化合物或含氟长链烷基酯胺类化合物及其公斤级制备方法 |
| CN113264842B (zh) | 2021-07-21 | 2022-03-01 | 苏州科锐迈德生物医药科技有限公司 | 一种脂质化合物及包含其的脂质载体、核酸脂质纳米粒组合物和药物制剂 |
| PL4426270T3 (pl) | 2021-11-02 | 2025-11-24 | Ziphius Nv | Nanocząsteczki lipidowe do dostarczania oligonukleotydów |
| JP2024542188A (ja) | 2021-11-16 | 2024-11-13 | セイル バイオメディシンズ インコーポレイテッド | 新規イオン化可能な脂質および脂質ナノ粒子ならびにそれらを使用する方法 |
| CA3242402A1 (en) | 2021-12-16 | 2023-06-22 | Acuitas Therapeutics, Inc. | Lipids for use in lipid nanoparticle formulations |
| JP2025530171A (ja) | 2022-09-07 | 2025-09-11 | アクイタス セラピューティクス インコーポレイテッド | 脂質ナノ粒子製剤で使用するための脂質 |
| CN121443580A (zh) | 2023-05-05 | 2026-01-30 | 爱康泰生治疗公司 | 用于脂质纳米颗粒制剂的脂质 |
-
2019
- 2019-10-18 CA CA3116576A patent/CA3116576A1/en active Pending
- 2019-10-18 JP JP2021521190A patent/JP7543259B2/ja active Active
- 2019-10-18 US US17/286,134 patent/US12583816B2/en active Active
- 2019-10-18 WO PCT/US2019/056944 patent/WO2020081938A1/en not_active Ceased
- 2019-10-18 EP EP19798469.3A patent/EP3867225A1/en active Pending
- 2019-10-18 AU AU2019361129A patent/AU2019361129A1/en not_active Abandoned
-
2021
- 2021-04-13 IL IL282288A patent/IL282288A/en unknown
-
2024
- 2024-08-21 JP JP2024139437A patent/JP7848275B2/ja active Active
-
2025
- 2025-04-09 AU AU2025202533A patent/AU2025202533A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL282288A (en) | 2021-05-31 |
| US12583816B2 (en) | 2026-03-24 |
| JP2024174889A (ja) | 2024-12-17 |
| US20210395188A1 (en) | 2021-12-23 |
| EP3867225A1 (en) | 2021-08-25 |
| JP7848275B2 (ja) | 2026-04-20 |
| AU2025202533A1 (en) | 2025-05-01 |
| AU2019361129A1 (en) | 2021-05-20 |
| WO2020081938A1 (en) | 2020-04-23 |
| JP7543259B2 (ja) | 2024-09-02 |
| JP2022505234A (ja) | 2022-01-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12583816B2 (en) | Lipids for lipid nanoparticle delivery of active agents | |
| US12410121B2 (en) | Cationic lipids for use in lipid nanoparticles | |
| US11357856B2 (en) | Lipids for delivery of active agents | |
| US12151996B2 (en) | Lipids for lipid nanoparticle delivery of active agents | |
| US11524932B2 (en) | Lipids for use in lipid nanoparticle formulations | |
| US12065396B2 (en) | Lipids for use in lipid nanoparticle formulations | |
| US11639329B2 (en) | Lipids for use in lipid nanoparticle formulations | |
| US11040112B2 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| WO2025217264A1 (en) | Cationic lipid compounds for use in lipid nanoparticles | |
| US20250188016A1 (en) | Cationic lipid compounds for use in lipid nanoparticles | |
| US20250236586A1 (en) | Lipids for lipid nanoparticle delivery of active agents | |
| WO2025106806A1 (en) | Pegylated lipids | |
| WO2025231114A1 (en) | Method of using lipid nanoparticles for intramuscular delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241011 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241017 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20241017 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241123 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241216 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241216 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250424 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251010 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251010 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20251104 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20260304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260311 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260311 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260311 |